REBORN project contract signed

The signing of the REBORN contract marks a major step forward in the Inlog Group’s digital transition in transfusion informatics.

Vienna, Austria – December 5, 2023

On 5 December 2023, a significant event took place in Vienna, Austria, marking the official launch of the REBORN project. The contract was formally signed at a ceremony attended by key figures including David Kalfon, CEO of Inlog, Mr Peter Kaiser, Deputy Secretary General of the Austrian Red Cross, Mr Markus Jarning, Head of the Blood Service Division of the Austrian Red Cross, and Mr Gerhard Jirsa, Head of IT at the Blood Transfusion Centre.

REBORN, which stands for ‘Refactoring – Edge – Blood – Over – Responsive – New Technology’, symbolises the new chapter in the project, which aims to modernise and develop the current software solution, EdgeBlood, using the latest web technologies.

This major project is a collaboration between software publisher Inlog and several Austrian Red Cross institutions, with Vienna as the main sponsor. REBORN’s main objective is to redevelop the blood management solution using modern technological innovations.

The signing of the contract marks the start of a major digital transition for Inlog, a renowned software solutions company. David Kalfon, Inlog’s CEO, expressed his enthusiasm for this strategic partnership, underlining the importance of meeting today’s challenges in the medical sector with innovative technological solutions.

The REBORN project will extend over several years, gradually rolling out software modules that are improved each year. This phased approach will ensure the stability of the system while integrating the latest technological advances in a seamless manner and supporting the change process for user establishments. Inlog’s teams will work closely with the functional and technical teams of the Red Cross facilities in Austria to ensure the continued success and relevance of the project.

This initiative will contribute to the improvement of blood transfusion services and help to strengthen the operational efficiency and traceability of blood products in the country.